Skye Bioscience Inc (SKYE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$2.23+18.62%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Skye Bioscience advances nimacimab through clinical trials with key milestones expected by Q4 2026. The company manages capital to fund operations through late 2026 despite net losses of $9.7M to $18M per quarter. Strategic partnership with Halozyme supports drug delivery development. Approval to open a second cohort in a study reinforces clinical progress.
Skye faces ongoing net losses and negative cash flow with no revenue yet. Nasdaq delisting notices in March and May 2026 threaten listing status. EPS estimates remain negative at -$1.05 for 2026 and -$1.13 for 2027, showing no near-term profitability. Management remains volatile with recent CFO turnover.
The market reflects a sharp selloff with a 33.7% drawdown from highs and no clear consensus on revenue growth or fair value. Our view differs by focusing on clinical progress and capital runway, which are not yet priced in due to ongoing losses and regulatory risks.
Breaks if: Capital runs out before Q4 2026
Breaks if: Failure to achieve key clinical milestones by Q4 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is weakened, as recent financial performance has declined, and the company is navigating significant operational risks.
The market appears to be pricing in elevated risks, given the company's loss-making status and recent negative developments. The expectations seem to reflect a cautious outlook, particularly in light of potential guidance cuts and ongoing recession fears.
Fundamentals may remain under pressure due to ongoing operating losses and the need for capital discipline. Management's focus on integrating Redx Pharma and advancing clinical studies could provide some stability, but execution risks are high.
The long-term thesis hinges on successful integration of Redx Pharma and advancements in clinical trials. Additionally, the performance of sector bellwethers and broader economic conditions will significantly influence SKYE's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance fell from the top half to the bottom half of its industry. This change indicates a weakened reason to own the stock. However, the company announced a complete acquisition of Redx Pharma, which supports its strategic pivot. This acquisition enhances growth potential and strategic partnerships.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on progressing nimacimab through clinical trials and achieving key clinical milestones.
Breaks if: Failure to advance drug delivery development via partnership by end 2027
In the next 1-3 years, SKYE's outlook is uncertain, with several factors that could impact its performance. Not investment advice.